MXPA03005677A - Formas de dosis de sodio de divalproex y un proceso para su produccion. - Google Patents

Formas de dosis de sodio de divalproex y un proceso para su produccion.

Info

Publication number
MXPA03005677A
MXPA03005677A MXPA03005677A MXPA03005677A MXPA03005677A MX PA03005677 A MXPA03005677 A MX PA03005677A MX PA03005677 A MXPA03005677 A MX PA03005677A MX PA03005677 A MXPA03005677 A MX PA03005677A MX PA03005677 A MXPA03005677 A MX PA03005677A
Authority
MX
Mexico
Prior art keywords
dosage forms
divalproex sodium
production
sodium dosage
divalproex
Prior art date
Application number
MXPA03005677A
Other languages
English (en)
Inventor
R Engh Kevin
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MXPA03005677A publication Critical patent/MXPA03005677A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion se dirige a un proceso nuevo para la granulacion de compuestos de valproato, tales como sodio de divalproex, en el cual el compuesto se fusiona en ausencia de un aglutinante y se mezcla con uno o mas excipientes para producir granulos. Las formas de dosis resultantes tienen un factor de carga de farmaco incrementado en el rango de 75% p/p hasta 90% p/p.
MXPA03005677A 2000-12-22 2001-11-27 Formas de dosis de sodio de divalproex y un proceso para su produccion. MXPA03005677A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/747,912 US20020132010A1 (en) 2000-12-22 2000-12-22 Divalproex sodium dosage forms and a process for their production
PCT/US2001/043157 WO2002051399A2 (en) 2000-12-22 2001-11-27 Divalproex sodium dosage forms and a process for their production

Publications (1)

Publication Number Publication Date
MXPA03005677A true MXPA03005677A (es) 2004-04-21

Family

ID=25007215

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03005677A MXPA03005677A (es) 2000-12-22 2001-11-27 Formas de dosis de sodio de divalproex y un proceso para su produccion.

Country Status (5)

Country Link
US (1) US20020132010A1 (es)
BR (1) BR0112672A (es)
CA (1) CA2431415A1 (es)
MX (1) MXPA03005677A (es)
WO (1) WO2002051399A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040005357A1 (en) * 2002-07-03 2004-01-08 Sherman Bernard Charles Extended-release tablets comprising divalproex sodium
US20070134315A1 (en) * 2005-12-08 2007-06-14 Viera Michael L Orally administrable extended release pellet and tablet formulations of a highly water soluble compound
WO2008001151A1 (en) * 2006-06-29 2008-01-03 Wockhardt Limited Controlled release compositions of divalproex sodium
US20170273923A1 (en) * 2016-03-23 2017-09-28 Sun Pharmaceutical Industries Ltd. Method of administering divalproex

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL72381A (en) * 1983-07-20 1988-03-31 Sanofi Sa Pharmaceutical composition based on valproic acid
GB9201857D0 (en) * 1992-01-29 1992-03-18 Smithkline Beecham Plc Novel compound
US6287598B1 (en) * 1993-05-28 2001-09-11 Alza Corporation Method for providing sustained antiepileptic therapy
EP0818990A1 (en) * 1995-04-03 1998-01-21 Abbott Laboratories Homogeneous mixtures of low temperature-melting drugs and additives for controlled release
WO1998040060A1 (en) * 1997-03-11 1998-09-17 Hexal Ag Solid, non-deliquescent formulations of sodium valproate

Also Published As

Publication number Publication date
CA2431415A1 (en) 2002-07-04
WO2002051399A3 (en) 2003-01-16
BR0112672A (pt) 2004-02-03
WO2002051399A2 (en) 2002-07-04
US20020132010A1 (en) 2002-09-19

Similar Documents

Publication Publication Date Title
RS50140B (sr) Postupak za dobijanje perkihinina i njegova upotreba
BG104412A (en) Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
GEP20022678B (en) Bicyclic Heteroaromatic Compounds As Protein Tyrosine Kinase Inhibitors, their Pharmaceutical compositions and methods for Treatment
AP2002002637A0 (en) Novel piperazine
MY113274A (en) Omeprazole magnesium salt form
JO2372B1 (en) Source drugs of 4-phenylpyridine derivatives
AU2364600A (en) Heteroroaromatic amides as inhibitor of factor xa
DK0673245T3 (da) Farmaceutisk brusepræparat indeholdende ibuprofen og fremgangsmåde til dets fremstilling.
EA200301040A1 (ru) Способ производства фармацевтической композиции низкой дозы
MXPA03011954A (es) Nuevos derivados de acido sulfonico.
BG106927A (en) Matrix tablet for prolonged release of trimetazidine after oral administration
MX9704856A (es) Derivados de indazol sustituidos.
NO20023551L (no) Ibuprofen-inneholdende aktivt middel-preparat
MY119090A (en) Synthetic polysaccharides, process for their preparation and pharmaceutical compositions containing them
HRP20030002A2 (en) STABLE GABAPENTIN HAVING pH WITHIN A CONTROLLED RANGE
EA200400061A1 (ru) Фармацевтический состав с замаскированным вкусом и способ его получения
MXPA03005677A (es) Formas de dosis de sodio de divalproex y un proceso para su produccion.
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
BR0114380A (pt) Derivados-1-aminobutan-3-ol-substituìdos
IL105276A (en) (S)-a-PHENYL- 2-PYRIDINEETHANAMINE, ITS PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
CA2344686A1 (en) High purity composition comprising (7.alpha.,17.alpha.)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one
BG106414A (en) Bioavailable dosage form of isotretinoin
MXPA03008837A (es) Una composicion farmaceutica estable de pravastatina.
MXPA03005676A (es) Formas de dosis solidas de sodio de divalproex.
MXPA04004090A (es) Compuestos substituidos de 1h-quinolin-2-ona.